In today’s medical development, diagnosed tuberculosis is generally curable as long as it is seen in a timely manner and receives regular treatment. However, the reality is that some patients eventually become drug-resistant TB after experiencing repeated alternations of improvement and deterioration, and after a long period of untreated treatment. Drug-resistant tuberculosis refers to patients with tuberculosis resistant to one or more anti-tuberculosis drugs. Multidrug-resistant TB is part of drug-resistant TB, which simply means TB in which the tubercle bacilli are resistant to both isoniazid and rifampin, the two main antituberculosis drugs. The following four conditions are highly suspicious of the possibility of multidrug-resistant tuberculosis: 1. TB symptoms have not improved significantly after taking first-line anti-tuberculosis drugs, or lesions have not been significantly absorbed after treatment; 2. People who have had previous TB disease and have not been treated regularly, and whose symptoms have not improved significantly or lesions have not been significantly absorbed after treatment again after relapse; 3. People who have been in close contact with drug-resistant TB patients; 4. Patients with tuberculosis whose sputum smear continued to be positive during the course of treatment. In the past, to determine whether a TB patient was multidrug-resistant TB, a sputum TB culture was required, and a positive culture was followed by a drug sensitivity test, which took a total of 2 to 3 months. The gene chip technology currently being developed in our hospital can provide results in about 2 days. In order to get accurate results, patients need to be reminded to pay attention to the quality of sputum retained and to make sure to try to cough up sputum from deep in the trachea. If there is really no sputum, nebulization to induce sputum or bronchoscopic alveolar lavage fluid can be taken. Multidrug-resistant tuberculosis is difficult and expensive to treat, and more seriously, individuals infected by these patients are multidrug-resistant tuberculosis patients once they develop the disease. Therefore, in order to effectively control and manage multidrug-resistant tuberculosis, our hospital has set up a special multidrug-resistant tuberculosis ward (internal eight department), introduced international and domestic advanced experience and the latest technology in treating multidrug-resistant tuberculosis, combined with each patient’s condition, and taken Individualized and comprehensive treatment measures, i.e. the selection of sensitive anti-tuberculosis western drugs and some new drugs, Chinese herbal medicine, immunotherapy, interventional therapy, psychological intervention, etc., so that each patient with drug-resistant TB can receive scientific, standardized and reasonable treatment. In order to reduce the economic burden of NNCC patients, the state classifies multidrug-resistant TB as a major disease and gives the greatest preference in medical insurance reimbursement, i.e. an enrolled multidrug-resistant TB patient can spend a maximum of 17,000 medical expenses in one visit and get a 70% reimbursement rate when he returns to the local NNCC administration.